BioNotebook: Bayer invests in Versant's VC fund; corporate venture data; Triphase/Celgene deals

Bayer HealthCare will invest up to $25m in the fifth venture capital fund raised by Versant Ventures, which may exceed $300m, to finance early-stage therapeutic innovation and extend the company's relationship with the VC firm.